novo nordisk glp 1 oral to launch Ozempic for type 2 diabetes in US Novo Nordisk expands oral GLP-1

Safety Concerns: Without comprehensive human trials, the FDA cannot assure the safety of BPC-157, including potential side effects, long-term impacts, and appropriate dosages

This novel pathway functions in the absence of scavenging proteins Hp and Hx, a scenario that is highly clinically relevant

Consistent with the base-case analysis, sensitivity analyses demonstrated that using GLP-1RAs versus insulin was either cost-saving or cost-effective, except for the analyses where the treatment effectiveness was estimated based on the AT scenario in the second and third sensitivity analyses, showing that a GLP-1RA versus insulin therapy was not cost-effective for averting one case of all-cause death from the payer perspective

Noctor, G., Queval, G., Mhamdi, A., Chaouch, S